Meanwhile, IL-17 has been observed to cause CD8 cytotoxic T cell (CTL) desensitization in a mouse model of PD-1 antibody-resistant lung cancer and to promote tumor sensitivity to IL-6 and neutrophil depletion in Kras lung tumors in IL-17 transgenic mice, both of which make PD-1 immune checkpoint therapy-resistant (126, 208). This evidence concerns the gene IL17A and lung carcinoma.